Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) was up 9% during trading on Monday after Barclays raised their price target on the stock from $60.00 to $62.00. Barclays currently has an overweight rating on the stock. Tarsus Pharmaceuticals traded as high as $52.20 and last traded at $53.16. Approximately 140,704 shares traded hands during trading, a decline of 81% from the average daily volume of 750,498 shares. The stock had previously closed at $48.78.
Several other research analysts have also commented on TARS. The Goldman Sachs Group boosted their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $56.00.
Get Our Latest Stock Analysis on TARS
Institutional Investors Weigh In On Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Price Performance
The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The firm has a fifty day simple moving average of $51.26 and a 200 day simple moving average of $39.40. The company has a market capitalization of $1.95 billion, a PE ratio of -13.40 and a beta of 1.02.
Tarsus Pharmaceuticals Company Profile
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Articles
- Five stocks we like better than Tarsus Pharmaceuticals
- What is an Earnings Surprise?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- How to Use Stock Screeners to Find Stocks
- What Does the Future Hold for Eli Lilly?
- Canadian Penny Stocks: Can They Make You Rich?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.